Treating Early-Stage Lung Cancer With Immunotherapies

home / case-based-roundtable-series / treating-early-stage-lung-cancer-with-immunotherapies

This roundtable series delves into therapies used for limited-stage small cell lung cancer or early-stage non–small cell lung cancer, as discussed by participants at virtual live events.

Part 1: Using Adjuvant Chemotherapy for EGFR-Positive NSCLC

Part 1: Using Adjuvant Chemotherapy for EGFR-Positive NSCLC

Targeted Oncology Staff
March 14th 2022

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

Part 2: Barriers and Sequencing for Osimertinib in EGFR+ NSCLC

Part 2: Barriers and Sequencing for Osimertinib in EGFR+ NSCLC

Targeted Oncology Staff
April 11th 2022

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.

Part 1: Barriers to Rapid Molecular Testing for Early-Stage Lung Cancer

Part 1: Barriers to Rapid Molecular Testing for Early-Stage Lung Cancer

Targeted Oncology Staff
May 31st 2022

During a live virtual event, Aaron E. Lisberg, MD, discussed the value of molecular testing in patients recently diagnosed with early-stage lung cancer.

Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC

Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLC

Targeted Oncology Staff
June 13th 2022

During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.

The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC

The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC

Targeted Oncology Staff
January 24th 2023

During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.

Chemotherapy’s Role Reevaluated in Early-Stage EGFR+ NSCLC

Chemotherapy’s Role Reevaluated in Early-Stage EGFR+ NSCLC

Targeted Oncology Staff
February 10th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, discussed the use of adjuvant therapies including chemotherapy and osimertinib in patients with non–small cell lung cancer.